SCHEMBL5455798

SCHEMBL5455798

CCOc1ccc2c(C(N)=O)c(NC(=O)Nc3ccc(F)cc3)sc2c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 11/20 0.47
NPC1 O15118 3/20 0.47
RAB9A P51151 3/20 0.47
SMN1; SMN2 Q16637 3/20 0.47
PKM P14618 2/20 0.47
KMT2A Q03164 8/20 0.45
MEN1 O00255 7/20 0.45
POLB P06746 2/20 0.45
USP2 O75604 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
KDM4E B2RXH2 3/20 0.45
LMNA P02545 2/20 0.45
PAX8 Q06710 1/20 0.45
ALDH1A1 P00352 4/20 0.43
FAAH O00519 1/20 0.43
NPSR1 Q6W5P4 2/20 0.42
CASP3 P42574 1/20 0.42
TRPV1 Q8NER1 1/20 0.42
SENP7 Q9BQF6 1/20 0.42
GAA P10253 2/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5460276 0.94 MAPT (0.51) MAPTNPC1RAB9ASMN1; SMN2PKM
SCHEMBL5448415 0.91 MAPT (0.50) MAPTNPC1RAB9ASMN1; SMN2PKM
SCHEMBL5457894 0.91 MAPT (0.46) MAPTNPC1RAB9ASMN1; SMN2PKM
SCHEMBL5451259 0.90 MAPT (0.47) MAPTNPC1RAB9ASMN1; SMN2PKM
SCHEMBL5460194 0.90 MAPT (0.57) MAPTNPC1RAB9ASMN1; SMN2PKM
SCHEMBL5455953 0.89 MEN1 (0.47) MAPTNPC1RAB9ASMN1; SMN2PKM
SCHEMBL5449712 0.88 MAPT (0.44) MAPTNPC1RAB9ASMN1; SMN2PKM
SCHEMBL5451885 0.87 POLB (0.51) MAPTNPC1RAB9ASMN1; SMN2PKM
SCHEMBL5456387 0.87 KMT2A (0.51) MAPTNPC1RAB9ASMN1; SMN2PKM
SCHEMBL5453549 0.86 MEN1 (0.46) MAPTNPC1RAB9ASMN1; SMN2PKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US claimed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP claimed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO claimed
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents GPC BIOTECH AG (DE) 2007-11-29 US disclosed
EP-1670804-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC Biotech AG (DE) 2006-06-21 EP disclosed
WO-2005023818-A2 HETEROBICYCLIC COMPOUNDS AS PHARMACEUTICALLY ACTIVE AGENTS GPC BIOTECH AG (DE) 2005-03-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070275962-A1 Heterobicyclic Compounds as Pharmaceutically Active Agents TBCA, PARK7, NFATC1 MAPT 21/4885NPC1 2627/4885RAB9A 948/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.